BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharmaconomics//FDA Catalyst Calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
BEGIN:VEVENT
UID:pharmaconomics-339@pharmaconomics
DTSTAMP:20260707T003841Z
DTSTART;VALUE=DATE:20260827
DTEND;VALUE=DATE:20260828
SUMMARY:GILD PDUFA — bictegravir and lenacapavir
DESCRIPTION:The FDA's approval decision on bictegravir and lenacapavir for virologically suppressed people with HIV is due Aug 27\, 2026. A green light opens the market\; a complete response letter (CRL) usually sinks the stock.\n\nPrimary source: https://www.sec.gov/Archives/edgar/data/882095/000088209526000022/exhibit991earningspressrel.htm\n\nTrack it: https://www.pharmaconomics.com/e/339
URL:https://www.pharmaconomics.com/e/339
TRANSP:TRANSPARENT
BEGIN:VALARM
TRIGGER:-P1D
ACTION:DISPLAY
DESCRIPTION:GILD catalyst tomorrow
END:VALARM
END:VEVENT
END:VCALENDAR